SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-12-056527
Filing Date
2012-08-09
Accepted
2012-08-09 16:01:27
Documents
10
Period of Report
2012-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q a12-13890_110q.htm 10-Q 865270
2 EX-31.1 a12-13890_1ex31d1.htm EX-31.1 12501
3 EX-31.2 a12-13890_1ex31d2.htm EX-31.2 12515
4 EX-32.1 a12-13890_1ex32d1.htm EX-32.1 8041
  Complete submission text file 0001104659-12-056527.txt   5535125

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT cldx-20120630.xml EX-101.INS 736049
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cldx-20120630.xsd EX-101.SCH 38717
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT cldx-20120630_cal.xml EX-101.CAL 69223
8 XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT cldx-20120630_lab.xml EX-101.LAB 648649
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cldx-20120630_pre.xml EX-101.PRE 303149
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cldx-20120630_def.xml EX-101.DEF 217416
Mailing Address 119 FOURTH AVE NEEDHAM MA 02494-2725
Business Address 119 FOURTH AVE NEEDHAM MA 02494 7814330771
Celldex Therapeutics, Inc. (Filer) CIK: 0000744218 (see all company filings)

IRS No.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-15006 | Film No.: 121020355
SIC: 2835 In Vitro & In Vivo Diagnostic Substances